Abstract
INTRODUCTION: Brazil ranks first in the number of HTLV-1/-2-infected individuals worldwide. The high morbidity and mortality of HTLV-1-associated diseases, especially following infection in infancy, requires strong action to reduce vertical transmission. METHODS: To facilitate the appraisal of the implementation of the HTLV antenatal screening program by the Brazilian Ministry of Health, we determined the costs in distinct scenarios according to HTLV seroprevalence, specificity of the screening test, and type of confirmatory test. RESULTS: HTLV antenatal screening would cost R$ 55,777,012-R$ 77,082,123/year. Screening assays with high specificity reduce the need and cost of confirmatory assays by up to 25%. CONCLUSIONS: Careful selection of the screening assay is required to optimize the program.
Highlights
Brazil ranks first in the number of Human T cell lymphotropic virus (HTLV)-1/-2-infected individuals worldwide
To facilitate the appraisal of the implementation of the HTLV antenatal screening program by the Brazilian Ministry of Health, we determined the costs in distinct scenarios according to HTLV seroprevalence, specificity of the screening test, and type of confirmatory test
The diagnosis of Human T-cell lymphotropic virus 1 (HTLV-1)/2 infection is based on the detection of anti-HTLV-1/2 antibodies using a screening assay, such as enzymelinked immunoassay (ELISA) or chemiluminescent immunoassay (CMIA), followed by confirmatory testing of the reactive samples
Summary
Brazil ranks first in the number of HTLV-1/-2-infected individuals worldwide. The high morbidity and mortality of HTLV-1associated diseases, especially following infection in infancy, requires strong action to reduce vertical transmission. The diagnosis of HTLV-1/2 infection is based on the detection of anti-HTLV-1/2 antibodies using a screening assay, such as enzymelinked immunoassay (ELISA) or chemiluminescent immunoassay (CMIA), followed by confirmatory testing of the reactive samples.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Revista da Sociedade Brasileira de Medicina Tropical
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
